LCMS
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike

High-Sensitivity Analysis of Drugs in Ultra-Small Volume Plasma Samples Using Microflow LC/MS/MS

Applications | 2020 | ShimadzuInstrumentation
LC/MS, LC/MS/MS, LC/QQQ
Industries
Pharma & Biopharma, Clinical Research
Manufacturer
Shimadzu

Summary

Importance of the Topic


Drug metabolism studies rely on sensitive detection of parent compounds and metabolites in biological samples. Conventional LC-MS/MS methods often require large sample volumes, raising ethical and cost concerns in preclinical pharmacokinetic research. Microflow LC-MS/MS addresses these challenges by enhancing sensitivity while reducing plasma volume requirements, enabling efficient drug quantitation in ultra-small samples.

Objectives and Study Overview


This study aimed to develop a high-sensitivity microflow LC-MS/MS method for quantifying Verapamil and its metabolite Nor-Verapamil in ultra-small (2 µL) rat plasma samples. The method performance was benchmarked against a conventional semi-microflow approach to demonstrate sensitivity gains and robustness.

Methodology and Instrumentation


The trap-and-elute workflow was implemented on a Shimadzu Nexera Mikros system, capable of flows from 1 to 500 µL/min. Plasma samples spiked with analytes and Verapamil-D6 internal standard were deproteinized with acetonitrile/formic acid, incubated, centrifuged, and 5 µL of supernatant injected.

Used Instrumentation


  • Shimadzu Nexera Mikros microflow LC-MS system
  • Shim-pack MC PLONAS Biphenyl analytical column (2.7 µm, 100 mm × 0.2 mm)
  • Shim-pack MCT LC8 trap column (5 µm, 5 mm × 0.3 mm)
  • Micro-ESI probe, LCMS-8060 mass spectrometer

Main Results and Discussion


Compared to semi-microflow analysis (100–500 µL/min), the microflow method (4 µL/min elution) achieved a 4.5-fold increase in Verapamil signal and 3.5-fold increase for Nor-Verapamil. Calibration curves over 0.5–181.6 µg/L showed excellent linearity (R2 > 0.998) and accuracy within 90–110% for both compounds. Trap-and-elute injection overcame peak broadening caused by acetonitrile in the sample matrix, maintaining narrow peaks and consistent retention.

Benefits and Practical Applications


  • Enhanced sensitivity allows reliable quantitation at low concentration levels in minimal plasma volume.
  • Reduced animal usage and sample consumption support ethical and cost-effective preclinical studies.
  • Robust microflow operation yields shorter analysis times and improved method stability versus nano-LC.

Future Trends and Applications


The integration of microflow LC-MS/MS with advanced micro-sampling techniques and automation is expected to further decrease sample requirements and increase throughput. Emerging developments in ionization technology and high-resolution mass spectrometry may expand applications to diverse biological matrices and multiplexed assays.

Conclusion


The trap-and-elute microflow LC-MS/MS method on the Shimadzu Nexera Mikros platform demonstrated significant sensitivity improvements for Verapamil and Nor-Verapamil analysis in ultra-small plasma samples. This approach supports efficient, ethical, and reliable preclinical pharmacokinetic investigations.

References


1 Rapid Communications in Mass Spectrometry, 2014, 28, 1293–1302.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Toggle
Shimadzu Microow Liquid Chromatography Mass Spectrometry System Nexera Mikros
C146-E350B Microflow Liquid Chromatography Mass Spectrometry System Nexera Mikros M i c r o: Above and Beyond Nano T h e High Sensitivit y You E x p e c t from a Low Flow Sys tem with the Ruggedness…
Key words
mikros, mikrosmicroflow, microflownexera, nexerashim, shimbonded, bondedmicro, micropack, packplonas, plonasphase, phaseverapamil, verapamilpolar, polarsystem, systempart, partmin, mindiameter
High-Sensitivity Analysis of Drugs in Ultra-Small Volumes Plasma Samples Using Micro-Flow LCMS/ MS
ThP 560 High-Sensitivity Analysis of Drugs in Ultra-Small Volumes Plasma Samples Using Micro-Flow LCMS/MS Davide VECCHIETTI1, Mikaël LEVI2, Hidetoshi TERADA1, Shinya IMAMURA1, Kyoko WATANABE1 1 SHIMADZU Corporation, LC Business Unit, Kyoto, Japan; 2 SHIMADZU Corporation, MS Business Unit, Kyoto, Japan;…
Key words
verapamil, verapamilmicro, micronor, norflow, flowmicroflow, microflowplasma, plasmamrm, mrmsensitivity, sensitivityimplementation, implementationsignal, signalnorverapamil, norverapamilxenobiotics, xenobioticsallowing, allowingmikros, mikrosrates
Microfow LC-MS/MS analysis of monoclonal antibody in human plasma at ng/mL level with nSMOL proteolysis
PO-CON1801E Microflow LC-MS/MS analysis of monoclonal antibody in human plasma at ng/mL level with nSMOL proteolysis. ASMS 2018 ThP-022 Kyoko Watanabe1 , Masateru Oguri1, Wataru Fukui1, Shinya Imamura1, Noriko Iwamoto2, Takashi Shimada2, Toshiya Matsubara1, Atsuhiko Toyama3, Kazuo Mukaibatake1, and Ichiro…
Key words
microflow, microflowantibody, antibodymonoclonal, monoclonalnsmol, nsmolplasma, plasmaqualifier, qualifierassay, assayantibodies, antibodiessensitivity, sensitivityalleviating, alleviatinglba, lbapeptide, peptidecdr, cdrspectrometric, spectrometricdead
Microflow LC-MS/MS Analysis of Monoclonal Antibody in Human Plasma at ng/mL Level with nSMOLTM Proteolysis
LAAN-A-LM-E146 Application News No. C176 Microflow Liquid Chromatography Mass Spectrometry System Microflow LC-MS/MS Analysis of Monoclonal Antibody in Human Plasma at ng/mL Level with nSMOLTM Proteolysis „ Abstract nSMOL proteolysis has been reported as the novel technology to standardize the…
Key words
nsmol, nsmolcup, cupplasma, plasmaqualifier, qualifierproteolysis, proteolysismicroflow, microflowtube, tubecdr, cdrspectrometric, spectrometricfilter, filterreaction, reactiontherapeutic, therapeuticmonoclonal, monoclonalsocket, socketassay
Other projects
GCMS
ICPMS
Follow us
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike